PARADIGM SHIFT TOWARDS THE DEVELOPMENT OF BIODEGRADABLE DRUGS
Manuela Jörg, Senior Lecturer, Monash University
Pharmaceutical contamination in our ecosystems is a growing concern. The benign-by-design approach aims to develop biodegradable drugs, reducing ecological impact without relying on wastewater treatment, which is inaccessible to many. Broad adoption of these principles requires training, awareness, and the development of new tools and frameworks in drug discovery.
1. How has the increasing recognition of pharmaceutical contamination influenced the shift towards biodegradable drug development?
The increasing recognition of pharmaceutical contamination in the environment has led to a shift in thinking, starting early consideration into the development of biodegradable drugs. This involves designing drugs that are both effective and environmentally friendly. Additionally, this shift has sparked conversations about creating new frameworks to assess the environmental impact of drugs before they are entering the market. However, widespread adoption of biodegradable drug development has not yet occurred.
2. Could you elaborate on the core principles of the benign-by-design approach and how it differentiates from traditional drug discovery models?
The benign-by-design approach focuses on developing environmentally friendly pharmaceuticals that degrade into harmless substances after use. This method involves modifying the molecular structure of drugs to enhance their biodegradability while maintaining therapeutic efficacy. In contrast, traditional drug discovery models prioritize efficacy and safety for human use, often overlooking environmental impacts. Traditional methods can result in persistent pharmaceuticals accumulating in ecosystems, posing risks to wildlife and water quality. By integrating environmental considerations in the drug development process, the benign-by-design approach aims to mitigate these long-term issues of drugs.
3. What strategies or frameworks do you propose to integrate biodegradability considerations into early-stage drug discovery pipelines?
Achieving greener and more sustainable drug discovery requires changes across multiple areas, including regulatory incentives and guidelines that encourage pharmaceutical companies to prioritize sustainability in their development processes. To integrate biodegradability considerations into early-stage drug discovery, the following strategies might be employed. First, leveraging computational modeling and predictive tools early in the development process can help identify and optimize biodegradable drug candidates. Second, adopting green chemistry principles, such as using environmentally friendly solvents and reagents, can reduce the environmental impact of drug synthesis. Third, incorporating environmental risk assessments alongside traditional efficacy and safety evaluations ensures that biodegradability is considered from the beginning. Additionally, fostering collaboration between chemists, biologists, and environmental scientists can lead to innovative solutions for designing biodegradable drugs.
4. What are the primary chemical and structural challenges in designing biodegradable drugs while maintaining therapeutic efficacy?
Modifying a drug's molecular structure to enhance biodegradability without compromising its ability to bind to the target is crucial. The compound must still interact effectively with the intended drug target, preserving key functional groups and interactions. Achieving the right balance between stability and degradation is essential — the drug must remain stable long enough in the physiological environment to be effective but degrade into non-toxic byproducts afterward in the environment.
5. In what ways can computational modeling and predictive tools be leveraged to assess and optimise the biodegradability of drug candidates?
The development of models predicting the environmental degradation pathways of pharmaceuticals is still in its early stages. However, with recent advances in predictive tools, there is little doubt that computational models will play a crucial role in predicting and optimising the biodegradability of drug candidates. Predictive tools already play an important role in drug discovery by predicting the physicochemical properties and toxicological liabilities of molecules. By integrating computational modeling and predictive tools to assess the environmental biodegradability of molecules into the existing drug development process, researchers will be able to make informed decisions to select drug candidates with both therapeutic efficacy and lower environmental impact.
6. How can educational institutions and training programmes be adapted to instill a stronger emphasis on sustainability within pharmaceutical sciences?
Educational institutions and training programs can enhance sustainability in pharmaceutical sciences by integrating the often-overlooked concept of "benign-by-design" into the curriculum. This approach emphasizes designing drugs that are less toxic and more environmentally friendly from the outset. While green chemistry practices, such as reducing and avoiding toxic solvents, are frequently taught, there is a need to expand this focus to include the biodegradability of drugs and their environmental impact post-excretion. By educating students on these aspects, future scientists will be better equipped to consider the full lifecycle of pharmaceuticals, ultimately leading to more sustainable practices in the industry.
7. How do you see academia and industry collaborating to drive the paradigm shift toward greener drug discovery and sustainable pharmaceutical development?
Within academia, there is a growing emphasis on performing translational research and providing students with industry experience in tertiary education to ensure their job-readiness. Sustainable drug discovery offers an additional opportunity for hands-on projects and internships focused on sustainability, providing practical experience and reinforcing theoretical knowledge. Collaborating with industry partners to develop case studies and real-world problem-solving exercises can further enhance learning outcomes. This collaboration benefits both academia and industry by fostering innovation and preparing a workforce skilled in sustainable practices. Additionally, fostering a culture of sustainability through workshops, seminars, and guest lectures from experts in the field will support the exchange of ideas and inspire students to prioritize eco-friendly practices in their future careers.
8. What role does public and policymaker awareness play in accelerating the transition toward environmentally benign drug design?
Public and policymaker awareness is crucial in accelerating the transition toward environmentally benign drug design. Increased awareness can drive demand for greener pharmaceuticals, encouraging pharmaceutical companies to prioritize sustainability in their research and development efforts. The implementation of policies and regulations that incentify and promote the development and use of environmentally biodegradable drugs might result in stricter environmental guidelines and support for sustainable drug prescribing practices. Additionally, public education campaigns can highlight the environmental impact of drugs, fostering a culture of responsible medication use and disposal.
9. Are there any notable success stories or case studies where biodegradable drugs have been effectively developed and implemented?
Biodegradable drugs do exist, showcasing that it is possible to create pharmaceuticals that break down naturally in the environment. However, many of these drugs were not intentionally designed with biodegradability in mind; their ability to decompose is a fortunate byproduct of their chemical structure. For example, certain antibiotics and pain relievers naturally break down in the environment due to their chemical structures. This unintentional biodegradability shows that with deliberate design, it is possible to develop drugs that are both effective and environmentally friendly. By focusing on green chemistry principles and considering the environmental impact of drugs post-excretion, the pharmaceutical industry can advance towards more sustainable practice. This approach not only benefits the environment but also aligns with the growing emphasis on sustainability in healthcare.
10. Given that wastewater treatment is not universally accessible, how can biodegradable drug development help mitigate contamination in resource-limited regions?
Biodegradable drug development can significantly mitigate contamination in resource-limited regions where wastewater treatment is not widely available. By designing drugs that break down into non-toxic byproducts, the environmental impact of pharmaceutical residues can be minimized. According to the World Health Organization, about 2.2 billion people globally don’t have access to safe drinking water. This issue is particularly severe in low-income regions such as Sub-Saharan Africa and parts of Asia, where inadequate infrastructure exacerbates the problem. By developing biodegradable drugs, we can help reduce the environmental burden in these vulnerable areas, promoting both ecological and human health. This approach reduces the accumulation of persistent pharmaceuticals in water sources, which is crucial for protecting local ecosystems and public health. Additionally, biodegradable drugs can help prevent the long-term contamination of soil and groundwater, which is often a challenge in areas lacking advanced waste management infrastructure.
11. Do you foresee any potential trade-offs or unintended consequences in prioritizing biodegradability in drug design, such as stability or efficacy concerns?
While the development of biodegradable drugs presents challenges, human health should always remain the highest priority. There should be no compromise in drug stability and efficacy. In some cases, the use of poorly biodegradable drugs might be justified, especially for rare conditions or in cases without alternative treatment options. However, prioritising the prescription and development of biodegradable drugs is crucial for a sustainable future. Although the cost of developing these drugs might be higher in some cases, it also opens up new commercial opportunities as the demand for eco-friendly medical solutions grows.
Furthermore, the environmental impact of non-biodegradable drugs, including contamination of water sources and ecosystems, poses significant risks to human health and indirectly results in additional costs to the health system. Pharmaceutical pollution can lead to issues like antibiotic resistance and other public health concerns. Therefore, while biodegradability is an important goal, it must be balanced with ensuring drug safety, efficacy, and accessibility. Careful consideration and a case-by-case approach are essential to navigate these trade-offs effectively.
Author Bio
Dr Manuela Jörg is a Senior Lecturer at the Monash Institute of Pharmaceutical Sciences. She obtained her PhD in medicinal chemistry from Monash University in 2014. Her research focuses on developing novel drugs using chemical probes to streamline the drug discovery process, while also creating awareness and tools to support greener drug discovery with reduced environmental impact.
